Lupin Pharmaceuticals Settles $30 Million Litigation with Humana Inc
Lupin's US arm signs $30 million litigation settlement with Humana Inc
Business Standard
Image: Business Standard
Lupin Pharmaceuticals, Inc USA has agreed to a $30 million settlement with Humana Inc to resolve litigation over alleged anti-competitive practices. The settlement is part of a broader case involving multiple defendants in the 'In Re Generic Pharmaceuticals Antitrust Litigation' in Philadelphia, Pennsylvania.
- 01Lupin Pharmaceuticals has settled for $30 million with Humana Inc.
- 02The settlement addresses allegations of anti-competitive practices.
- 03Lupin denies all allegations but chose to settle to avoid litigation costs.
- 04The case is part of the larger 'In Re Generic Pharmaceuticals Antitrust Litigation'.
- 05The settlement amount has been accounted for in Lupin's prior financial results.
Advertisement
In-Article Ad
Lupin Pharmaceuticals, Inc USA, a subsidiary of Lupin Ltd, has entered into a $30 million settlement agreement with Humana Inc to resolve litigation concerning alleged anti-competitive practices. The lawsuits, which involve claims of violations of federal and state antitrust laws, were consolidated into the 'In Re Generic Pharmaceuticals Antitrust Litigation' in Philadelphia, Pennsylvania. Although Lupin denies the allegations, the company opted to settle to mitigate the costs and uncertainties associated with ongoing litigation. The settlement ensures a full release of all claims against Lupin and its affiliates by Humana, and this amount has already been included in the company's previous financial results. Importantly, the settlement explicitly states that Lupin denies any admission of liability or unlawful conduct.
Advertisement
In-Article Ad
The settlement may affect Lupin's financial standing but allows the company to avoid prolonged litigation costs, which could have broader implications for its operations and product pricing.
Advertisement
In-Article Ad
Reader Poll
Do you believe pharmaceutical companies should be held accountable for anti-competitive practices?
Connecting to poll...
Read the original article
Visit the source for the complete story.